<div class="headers"><div>Figure 2 Comparison of 220 mg and 150 mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed
according to the type of anaesthesia: (A) major venous thromboembolism (VTE) and VTE-related mortality; (B) major bleeding events; (C) major bleeding events plus clinically relevant bleeding events. Data are presented as the odds ratio with 95% confidence intervals.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 2 Comparison of 220 mg and 150 mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed
according to the type of anaesthesia: (A) major venous thromboembolism (VTE) and VTE-related mortality; (B) major bleeding events; (C) major bleeding events plus clinically relevant bleeding events.</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class=""> Data are presented as the odds ratio with 95% confidence intervals.</p></td>
</tr>
</tbody>
</table>
